Bone Cell Biology and Disease - Senior Research Staff - A/Prof Evange Romas

A/Prof Evange Romas

MBBS, PhD, FRACP
Rheumatology Research Group Leader
Director, Department of Rheumatology, St. Vincent’s Hospital

Education and Professional Experience

1986      MBBS, The University of Melbourne, Melbourne, Australia
1993      FRACP, The Royal Australasian College of Physicians
1999      PhD, The University of Melbourne, Melbourne, Australia

Achievements

2011      Chair, Therapeutics Committee, Australian Rheumatology Association
2007      Chair, Scientific and Program Committee, Australian Rheumatology Association
1999      Senior Investigator Award, Australian Rheumatology Association
1995      Young Investigator Award, American Society for Bone and Mineral Research

Research Interests

Mechanisms of Inflammatory bone loss
Targeted therapeutics for rheumatoid and osteoarthritis
Bone remodeling in arthritis and how this process is controlled by cytokines

Selected Publications

    1. Le Goff B, Romas E, Walsh N. IL-6 is a critical cytokine for inflammatory bone loss in rheumatoid arthritis. Int. J. Clin. Rheumatol. 2010; 5(6), 609–612
    2. Le Goff B, Berthelot JM, Maugars Y, Romas E. Alternative use of Bisphosphonate  Therapy for Rheumatic Diseases. Curr Pharm Des. 2010; 16(27):3045-52
    3. Romas E. Clinical Applications of RANK-ligand Inhibition. Internal Medicine Journal 2009; 39, 110–16
    4. Romas E. Corticosteroid-induced osteoporosis and fractures. Australian Prescriber. 2008; 31, 45-49
    5. Romas E & Gillespie MT. Inflammatory Bone Loss – can it be prevented? Rheumatic Disease Clinics of North America. 2006; 32(4), 759-73
    6. Sims NA, Green JR, Glatt M, Schlicht S, Martin TJ, Gillespie MT, Romas E. Targeting osteoclasts with zoledronic acid prevents bone destruction in collagen-induced arthritis. Arthritis Rheum. 2004; 50, 2338-46
    7. Romas E, Gillespie MT, Martin TJ. Involvement of RANKL and tumor necrosis factor in bone destruction in rheumatoid arthritis. Bone. 2002; 30: 340-6
    8. Romas E, Sims NA, Hards D, Lindsay M, Ryan PFJ, Dunstan C, Martin TJ, Gillespie, MT. Osteoprotegerin reduces osteoclast numbers and prevents bone destruction in rats with collagen-induced arthritis. American Journal of Pathology. 2002; 162: 1419-27
    9. Romas E, Bakharevski O, Hards D, Kartsogiannis V, Quinn JM, Ryan PF, Martin TJ, Gillespie MT. Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis. Arthritis Rheum. 2000; 43, 821-6
    10. Horwood NJ, Kartsogiannis V, Quinn JM, Romas E, Martin TJ, Gillespie MT. Activated T lymphocytes support osteoclast formation in vitro. Biochem Biophys Res Commun. 1999; 265(1):144-50